NasdaqGM - Nasdaq Real Time Price USD
Affimed N.V. (AFMD)
0.1815
-0.0975
(-34.95%)
At close: May 19 at 4:00:00 PM EDT
0.1731
-0.01
(-4.63%)
After hours: May 19 at 7:58:17 PM EDT
Research Analysis
Earnings Estimate
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.87 | -0.55 | -4.07 | -1.87 |
| Low Estimate | -0.89 | -0.62 | -4.09 | -2.88 |
| High Estimate | -0.84 | -0.48 | -4.06 | -0.86 |
| Year Ago EPS | -6.52 | -1.27 | -7.09 | -4.07 |
Revenue Estimate
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 118.33k | 1.2M | 739.67k | 1.79M |
| Low Estimate | -- | -- | 600k | -- |
| High Estimate | 200k | 3.1M | 1M | 3.36M |
| Year Ago Sales | 413k | 155k | 8.28M | 739.67k |
| Sales Growth (year/est) | -71.35% | 674.19% | -91.06% | 141.73% |
Earnings History
| Currency in EUR | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.61 | -1.58 | -1.02 | -0.95 |
| EPS Actual | -6.52 | -1.27 | -1.01 | -0.94 |
| Difference | -4.91 | 0.31 | 0.01 | 0.01 |
| Surprise % | -304.97% | 19.81% | 0.81% | 1.40% |
EPS Trend
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.87 | -0.55 | -4.07 | -1.87 |
| 7 Days Ago | -0.86 | -0.55 | -4.07 | -2.78 |
| 30 Days Ago | -0.86 | -0.55 | -4.07 | -2.78 |
| 60 Days Ago | -0.86 | -0.55 | -4.07 | -2.78 |
| 90 Days Ago | -0.86 | -0.55 | -4.07 | -2.78 |
EPS Revisions
| Currency in EUR | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 2 | 1 |
| Up Last 30 Days | 2 | 2 | 2 | 1 |
| Down Last 7 Days | 1 | 1 | 1 | -- |
| Down Last 30 Days | 1 | 1 | 1 | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AFMD | 86.73% | 56.69% | 42.52% | 54.11% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 5/14/2025 |
| Downgrade | Wells Fargo: Overweight to Equal-Weight | 5/13/2025 |
| Downgrade | Leerink Partners: Outperform to Market Perform | 5/13/2025 |
| Maintains | Wells Fargo: Overweight to Overweight | 12/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/10/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 11/19/2024 |
Related Tickers
INZY Inozyme Pharma, Inc.
3.9900
+1.01%
HCWB HCW Biologics Inc.
8.57
-4.25%
KLTO Klotho Neurosciences, Inc.
0.2310
+2.85%
NCNA NuCana plc
0.0482
+10.05%
CNSP CNS Pharmaceuticals, Inc.
1.2900
+0.78%
ABP Abpro Holdings, Inc.
0.2720
+18.26%
CTMX CytomX Therapeutics, Inc.
2.1300
+4.93%
XLO Xilio Therapeutics, Inc.
0.8800
+2.40%
PLRZ Polyrizon Ltd.
0.0066
0.00%
CABA Cabaletta Bio, Inc.
1.9200
-5.42%